Search Results for "michigan"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for michigan. Results 1 to 10 of 308 total matches.
Rabies Vaccine
The Medical Letter on Drugs and Therapeutics • Dec 28, 1990 (Issue 834)
in human diploid embryo cells. Rabies vaccine adsorbed (RVA), a new vaccine produced by the Michigan ...
Human rabies continues to be rare in the USA, but animal rabies is becoming more common. An animal epizootic in the mid-Atlantic states, involving especially raccoons, has recently spread into the northeastern states.
In Brief: Measles Outbreak
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008 (Issue 1287)
have been confirmed in
Michigan, Wisconsin, Hawaii, New York State,
Pennsylvania, Illinois and Virginia (CDC Health ...
The US Centers for Disease Control and Prevention (CDC) has reported that measles outbreaks have occurred in New York City, California and Arizona in 2008, and additional cases have been confirmed in Michigan, Wisconsin, Hawaii, New York State, Pennsylvania, Illinois and Virginia (CDC Health Advisory, May 1, 2008). To date, 63 of the 64 infected patients were unvaccinated, and 54 of the cases were associated with importation of the disease. Both measles infection and vaccination (2 doses at least 28 days apart, with the first dose no earlier than 12 months of age) generally provide lifelong...
Hepatitis A Vaccine
The Medical Letter on Drugs and Therapeutics • Jun 09, 1995 (Issue 950)
from the Michigan
Department of Public Health (1-517-335-8120).
COST — A one-ml dose of Havrix costs ...
A vaccine to prevent hepatitis A (Havrix - SmithKline Beecham), previously licensed in more than 40 countries, including Canada, is now available in the United States. A similar vaccine manufactured by Merck is investigational in the USA.
Cord Blood Banks
The Medical Letter on Drugs and Therapeutics • Oct 01, 2001 (Issue 1114)
Region
Worcester, MA (508) 791-7444 ext. 135
UMASS Memorial Hospital, St. Vincent Hospital
Michigan ...
Pregnant women now often receive promotional material from private cord blood banks urging them to save and store their babies' cord blood.
Correction: Resperate for Hypertension
The Medical Letter on Drugs and Therapeutics • Aug 27, 2007 (Issue 1268)
EDITORIAL FELLOWS:
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein ...
(Med Lett Drugs Ther 2007; 49:55) The second sentence in the article ("The FDA does not require proof of effectiveness for approval of devices with minimal potential for harm, such as this one.") should have been omitted. It would apply to a Class I device, but the FDA has classified Resperate as a Class II device.
Correction: Low Dose Transdermal Estrogens
The Medical Letter on Drugs and Therapeutics • Oct 08, 2007 (Issue 1271)
EDITORIAL FELLOWS:
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein ...
The Medical Letter article (Med Lett Drugs Ther 2007; 49:71) on Low-Dose Transdermal Estrogens said that Elestrin has been marketed in Europe since 1976. Actually it is EstroGel (Ascend Therapeutics), a similar product, that has been available in Europe since 1976.
Addendum: Dermal Fillers
The Medical Letter on Drugs and Therapeutics • Jul 16, 2007 (Issue 1265)
EDITORIAL FELLOWS:
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein ...
Some Medical Letter consultants have suggested that our recent article on dermal fillers (Med Lett Drugs Ther 2007; 49:39) should have included stronger warnings about the risk of fillers that are not biodegradable, such as Artefill. The polymethylmethacrylate (PMMA, the same material that makes up Plexiglas) beads in Artefill can over time, even with the best technique, cause foreignbody granulomas and hypertrophic scarring, which may require surgical removal. Granulomas and nodules have been especially frequent when Artefill was injected into the lips. Complications are less likely with...
In Brief: Femcon Fe: A Chewable Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Feb 26, 2007 (Issue 1255)
:
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D., Albert ...
Femcon Fe (Warner Chilcott) is being advertised as the world's only chewable oral contraceptive. It was formerly marketed as Ovcon 35 Fe. Each packet provides 21 tablets containing 0.4 mg norethindrone and 35 mcg ethinyl estradiol, and 7 tablets with only 75 mg of ferrous fumarate. Femcon Fe has the same active hormonal ingredients as Ovcon 35 (Warner Chilcott), which has been available since 1976, and its generic equivalent Balziva (Barr); neither formulation contains iron. The spearmint-flavored Femcon Fe pill can be chewed or swallowed whole. According to the package labeling, if the pill...
In Brief: Varenicline (Chantix) Revisited
The Medical Letter on Drugs and Therapeutics • Nov 19, 2007 (Issue 1274)
., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein College of Medicine
SENIOR ...
When the nicotine receptor partial agonist varenicline (Chantix – Pfizer) was first marketed, The Medical Letter concluded that it was moderately effective in increasing smoking cessation rates.1 More recent publications and the clinical experience of Medical Letter consultants now suggest that varenicline is the most effective drug available for this indication, more effective than nicotine replacement therapy or bupropion SR (Zyban).2,3 A word of caution: exacerbations of psychiatric illness have been reported in patients who took higher-than-recommended starting doses of varenicline.4,5...
In Brief: Dexrazoxane for Anthracycline Extravasation
The Medical Letter on Drugs and Therapeutics • Dec 03, 2007 (Issue 1275)
., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein College of Medicine
SENIOR ...
The FDA has approved a new formulation of dexrazoxane (Totect) for treatment of extravasation from intravenous (IV) anthracyclines such as doxorubicin (Adriamycin, and others). Dexrazoxane has been available since 1995 as Zinecard for protection against the cardiac toxicity of anthracyclines (Med Lett Drugs Ther 1995; 37:110). It is also available generically. The drug’s precise mechanism of action is not known, but anthracyclines are vesicants that bind to DNA and act as oxidizing agents in the presence of iron. Dexrazoxane is a topoisomerase inhibitor, possibly interfering with...